查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594468

神经疼痛治疗药物市场：按治疗方法、适应症、分销管道 - 全球预测 2025-2030

Neuralgia Treatment Market by Treatment (Drug-Based, Surgery), Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

根据预测，2023年神经痛治疗市场价值为10.6亿美元，预计到2024年将达到12亿美元，复合年增长率为12.41%，到2030年将达到24.2亿美元。

神经痛药物是指治疗和缓解神经损伤、发炎和功能障碍引起的神经疼痛，常见于三叉神经痛和带状疱疹后遗症神经痛等疾病。对神经止痛药物的需求源于受影响个体的严重不适和生活品质下降，从而推动了对有效解决方案的持续需求。这些治疗方法范围从抗惊厥药和抗忧郁症等药物到神经阻断、神经调节甚至手术介入等先进治疗方法。最终用户包括医院、疼痛管理中心以及神经内科和神经外科诊所。神经病变疼痛疾病的增加、患者意识的提高以及药物开发和医疗技术的进步推动了市场的开拓。然而，治疗成本高、长期用药带来的副作用以及缺乏明确治疗方法等挑战可能会阻碍市场扩张。此外，低收入地区获得医疗保健的机会有限可能会限制治疗的采用。机会存在于创新领域，例如开发非侵入性神经调节剂、新型药物传输系统以及针对个人基因组成的个人化医疗方法。公司还可以探索人工智慧和机器学习，以增强诊断和治疗策略。鼓励官民合作关係并投资于研究，以最大限度地降低成本，同时最大限度地发挥影响力，也可以带来显着的好处。儘管有这些机会，监管障碍和临床试验的耗时性质仍然是重大障碍。竞争情势市场正在经历快速的技术进步和各大公司争夺市场占有率的竞争环境，需要不断的技术创新。持续监测新兴趋势，例如患者对微创治疗的偏好和疼痛管理的整体方法，对于希望利用这个动态市场的公司至关重要。

主要市场统计
基准年[2023] 10.6亿美元
预测年份 [2024] 12亿美元
预测年份 [2030] 24.2亿美元
复合年增长率（%） 12.41%

市场动态：揭示快速发展的神经疼痛药物市场的关键市场洞察

供需的动态交互作用正在改变神经止痛药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 由于人口老化，神经痛的发生率增加
    • 政府努力提高人们对神经疼痛治疗产品的认识
  • 市场限制因素
    • 神经疼痛治疗高成本
  • 市场机会
    • 技术进步将消除对药物和手术的需求
    • 新兴经济体外科和药物治疗的发展
  • 市场挑战
    • 药物的持续副作用

波特的五力：驾驭神经疼痛药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对神经痛治疗市场的影响

外部宏观环境因素在塑造神经痛治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解神经疼痛治疗药物市场的竞争状况

神经疼痛治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵神经痛治疗市场供应商的绩效评估

FPNV定位矩阵是评估神经痛治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划神经疼痛治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对神经疼痛治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着年龄的增长，神经痛的发生率增加
      • 政府采取措施提高人们对神经疼痛治疗产品的认识
    • 抑制因素
      • 治疗神经痛费用高
    • 机会
      • 技术进步将消除对药物和手术的需求
      • 新兴经济体外科和药物治疗的发展
    • 任务
      • 药物的持续副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗方式分類的神经痛治疗药物市场

  • 基于药物的
    • 抗惊厥药
    • 三环抗忧郁药物
  • 外科手术
    • 球囊压缩
    • 甘油注射液
    • 微血管减压手术
    • 射频烧伤治疗
    • 立体放射线手术

第七章依适应症分類的神经痛治疗药物市场

  • 糖尿病神经病变
  • 肋间神经痛
  • 枕神经痛
  • 週边神经痛
  • 带状疱疹后遗症神经痛
  • 三叉神经痛

第八章神经痛治疗药物市场：依通路分类

  • 药局
  • 医院药房
  • 网路药房
  • 零售药房

第九章 北美、南美神经痛治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太神经痛治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲神经痛治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Biogen Inc.
  • Cadila Healthcare
  • GLENMARK PHARMS LTD.
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals, Inc.
  • Lupin Limited
  • Merz Pharma GmbH & Co. KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teikoku Pharma USA, Inc.
  • Teva Pharmaceuticals Ltd.
  • Torrent Pharmaceuticals Ltd.
  • UCB Group
Product Code: MRR-F74E250AD635

The Neuralgia Treatment Market was valued at USD 1.06 billion in 2023, expected to reach USD 1.20 billion in 2024, and is projected to grow at a CAGR of 12.41%, to USD 2.42 billion by 2030.

Neuralgia treatment refers to the management and alleviation of nerve pain, which may arise due to damaged, irritated, or dysfunctional nerves often seen in conditions like trigeminal neuralgia and postherpetic neuralgia. The necessity of neuralgia treatment stems from the significant discomfort and reduced quality of life for affected individuals, fueling an ongoing demand for effective solutions. The application of these treatments spans pharmaceuticals, such as anticonvulsants and antidepressants, to advanced therapies like nerve blocks, neuromodulation, and even surgical interventions. End-users comprise hospitals, pain management centers, and specialty clinics dedicated to neurology and neurosurgery. Market growth is being driven by increasing incidences of neuropathic pain conditions, growing patient awareness, and advancements in drug development and medical technologies. However, challenges like high treatment costs, side effects associated with long-term medication use, and a lack of definitive cures can impede market expansion. Furthermore, limited healthcare access in low-income regions can restrict treatment uptake. Opportunities lie in innovative areas like developing non-invasive neuromodulation devices, novel drug delivery systems, and personalized medicine approaches tailored to an individual's genetic makeup. Companies can also explore artificial intelligence and machine learning to enhance diagnosis and treatment strategies. Encouraging public-private partnerships and investing in research to minimize costs while maximizing efficacy can also yield substantial benefits. Despite these opportunities, regulatory hurdles, and the time-consuming nature of clinical trials remain considerable barriers. The neuralgia treatment market is characterized by rapid technological advancements and a competitive landscape where major players vie for market share, prompting constant innovation. Continually monitoring emerging trends, such as patient preferences for minimally invasive treatments and holistic approaches to pain management, will be crucial for businesses aiming to capitalize on this dynamic market.

KEY MARKET STATISTICS
Base Year [2023] USD 1.06 billion
Estimated Year [2024] USD 1.20 billion
Forecast Year [2030] USD 2.42 billion
CAGR (%) 12.41%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuralgia Treatment Market

The Neuralgia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of neuralgia due to the rise in the aging population
    • Government initiatives to spread awareness regarding neuralgia treatment products
  • Market Restraints
    • High-cost associated with the treatment of neuralgia
  • Market Opportunities
    • Technological advancement eliminates the need for drugs and surgery
    • Developing surgical and pharmacological treatment in developing economies
  • Market Challenges
    • Persistent side effects from medications

Porter's Five Forces: A Strategic Tool for Navigating the Neuralgia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuralgia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuralgia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuralgia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuralgia Treatment Market

A detailed market share analysis in the Neuralgia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuralgia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuralgia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuralgia Treatment Market

A strategic analysis of the Neuralgia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuralgia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Biogen Inc., Cadila Healthcare, GLENMARK PHARMS LTD., H. Lundbeck A/S, Janssen Pharmaceuticals, Inc., Lupin Limited, Merz Pharma GmbH & Co. KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teikoku Pharma USA, Inc., Teva Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., and UCB Group.

Market Segmentation & Coverage

This research report categorizes the Neuralgia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Drug-Based and Surgery. The Drug-Based is further studied across Anticonvulsant Medicines and Tricyclic Antidepressants. The Surgery is further studied across Balloon Compression, Glycerol Injection, Microvascular Decompression, Radiofrequency Thermal Lesioning, and Stereotactic Radiosurgery.
  • Based on Indication, market is studied across Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, and Trigeminal Neuralgia.
  • Based on Distribution Channel, market is studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of neuralgia due to the rise in the aging population
      • 5.1.1.2. Government initiatives to spread awareness regarding neuralgia treatment products
    • 5.1.2. Restraints
      • 5.1.2.1. High-cost associated with the treatment of neuralgia
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement eliminates the need for drugs and surgery
      • 5.1.3.2. Developing surgical and pharmacological treatment in developing economies
    • 5.1.4. Challenges
      • 5.1.4.1. Persistent side effects from medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neuralgia Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Drug-Based
    • 6.2.1. Anticonvulsant Medicines
    • 6.2.2. Tricyclic Antidepressants
  • 6.3. Surgery
    • 6.3.1. Balloon Compression
    • 6.3.2. Glycerol Injection
    • 6.3.3. Microvascular Decompression
    • 6.3.4. Radiofrequency Thermal Lesioning
    • 6.3.5. Stereotactic Radiosurgery

7. Neuralgia Treatment Market, by Indication

  • 7.1. Introduction
  • 7.2. Diabetic Neuropathy
  • 7.3. Intercostal Neuralgia
  • 7.4. Occipital Neuralgia
  • 7.5. Peripheral Neuralgia
  • 7.6. Postherpetic Neuralgia
  • 7.7. Trigeminal Neuralgia

8. Neuralgia Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Drug Stores
  • 8.3. Hospital Pharmacies
  • 8.4. Online Pharmacies
  • 8.5. Retail Pharmacies

9. Americas Neuralgia Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Neuralgia Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Neuralgia Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Biogen Inc.
  • 3. Cadila Healthcare
  • 4. GLENMARK PHARMS LTD.
  • 5. H. Lundbeck A/S
  • 6. Janssen Pharmaceuticals, Inc.
  • 7. Lupin Limited
  • 8. Merz Pharma GmbH & Co. KGaA
  • 9. Novartis AG
  • 10. Pfizer Inc.
  • 11. Takeda Pharmaceutical Company Limited
  • 12. Teikoku Pharma USA, Inc.
  • 13. Teva Pharmaceuticals Ltd.
  • 14. Torrent Pharmaceuticals Ltd.
  • 15. UCB Group

LIST OF FIGURES

  • FIGURE 1. NEURALGIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. NEURALGIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. NEURALGIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. NEURALGIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEURALGIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEURALGIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTICONVULSANT MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY BALLOON COMPRESSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY GLYCEROL INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY MICROVASCULAR DECOMPRESSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RADIOFREQUENCY THERMAL LESIONING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INTERCOSTAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY OCCIPITAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PERIPHERAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 240. NEURALGIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 241. NEURALGIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023